Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg. The company has enclosed its press release on 21st October 2020.
The above information is a part of company’s filings submitted to BSE.